Cargando…
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
Acromegaly is a disease due to chronic GH excess and a consequent rise in IGF-1 levels. This rare endocrine condition is associated with metabolic alterations such as hyperglycaemia, dyslipidaemia, and systemic arterial hypertension, which, in addition to GH excess-related cardiovascular changes, pl...
Autores principales: | Puglisi, Soraya, Ferraù, Francesco, Ragonese, Marta, Spagnolo, Federica, Cannavò, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017075/ https://www.ncbi.nlm.nih.gov/pubmed/32117056 http://dx.doi.org/10.3389/fendo.2020.00028 |
Ejemplares similares
-
Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021) -
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment
por: Ferraù, Francesco, et al.
Publicado: (2018) -
Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly
Patients
por: Ragonese, Marta, et al.
Publicado: (2021) -
Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors
por: Re, Agnese, et al.
Publicado: (2020) -
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)